Ultragenyx Ownership
| RARE Stock | USD 38.86 0.78 1.97% |
Shares in Circulation | First Issued 2012-12-31 | Previous Quarter 95.5 M | Current Value 90.5 M | Avarage Shares Outstanding 51.8 M | Quarterly Volatility 21.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Ultragenyx |
Ultragenyx Stock Ownership Analysis
About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 6.29. Ultragenyx had not issued any dividends in recent years. The entity had 1:3 split on the 17th of January 2014. Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California. Ultragenyx Pharmaceu operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1119 people. To find out more about Ultragenyx contact the company at 415 483 8800 or learn more at https://www.ultragenyx.com.Besides selling stocks to institutional investors, Ultragenyx also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Ultragenyx's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Ultragenyx's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Ultragenyx Quarterly Liabilities And Stockholders Equity |
|
Ultragenyx Insider Trades History
Roughly 4.0% of Ultragenyx are currently held by insiders. Unlike Ultragenyx's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Ultragenyx's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Ultragenyx's insider trades
Ultragenyx Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ultragenyx is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ultragenyx backward and forwards among themselves. Ultragenyx's institutional investor refers to the entity that pools money to purchase Ultragenyx's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Deutsche Bank Ag | 2024-12-31 | 1.7 M | Alkeon Capital Management, Llc | 2024-12-31 | 1.7 M | Alliancebernstein L.p. | 2024-12-31 | 1.6 M | Baker Bros Advisors Lp | 2024-12-31 | 1.6 M | Geode Capital Management, Llc | 2024-12-31 | 1.6 M | Vestal Point Capital Lp | 2024-12-31 | 1.5 M | Alyeska Investment Group, L.p. | 2024-12-31 | 1.4 M | Adage Capital Partners Gp Llc | 2024-12-31 | 1.2 M | Point72 Asset Management, L.p. | 2024-12-31 | 1.2 M | Vanguard Group Inc | 2024-12-31 | 10 M | Blackrock Inc | 2024-12-31 | 6.5 M |
Ultragenyx Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ultragenyx insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ultragenyx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ultragenyx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ultragenyx Outstanding Bonds
Ultragenyx issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ultragenyx uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ultragenyx bonds can be classified according to their maturity, which is the date when Ultragenyx has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Ultragenyx Corporate Filings
F4 | 10th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 19th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 13th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 12th of February 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ultragenyx is a strong investment it is important to analyze Ultragenyx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ultragenyx's future performance. For an informed investment choice regarding Ultragenyx Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ultragenyx. If investors know Ultragenyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ultragenyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.29) | Revenue Per Share | Quarterly Revenue Growth 0.294 | Return On Assets | Return On Equity |
The market value of Ultragenyx is measured differently than its book value, which is the value of Ultragenyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ultragenyx's value that differs from its market value or its book value, called intrinsic value, which is Ultragenyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ultragenyx's market value can be influenced by many factors that don't directly affect Ultragenyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ultragenyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ultragenyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ultragenyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.